Regulatory News
Sunday, March 20, 2016
BRIEF-Amgen -Positive Top Line results from Phase 3 study evaluating Romosozumab in men with Osteoporosis
* Amgen And Ucb Announce Positive Top Line results from
Phase 3 study evaluating Romosozumab in men with Osteoporosis
Read more
No comments:
Post a Comment
‹
›
Home
View web version
No comments:
Post a Comment